EGFR lung cancer patients are missing trials they qualify for. Help us find out why.

We’re interviewing patients, caregivers, oncologists and trial sponsors to learn where the path to trials breaks down.

Healthy cell. Divides only when the body needs it.

The moment we study

One handoff decides whether a patient ever hears about a trial

For many people with EGFR-mutated lung cancer, the path looks like this. Our interviews focus on the single step where too many journeys quietly end.

  1. Diagnosis

    Testing finds an EGFR mutation, a target with real options.

  2. First-line therapy

    Targeted treatment begins, often with a strong response.

  3. Progression

    The cancer adapts and the first treatment stops working.

  4. The handoff

    Who raises trials, when, and with what information? This is what we are asking.

  5. A matching trial

    The destination exists. The question is who gets guided there.

Who we talk to

Four perspectives on the same broken path

A missed trial looks different depending on where you stand. We are listening to everyone who touches the journey, 15 minutes at a time.

  • Patients

    People living with EGFR lung cancer: what searching for a next option actually feels like when time matters.

  • Caregivers

    The partners and family members who research, call, and advocate. Often the real navigators of the system.

  • Oncologists

    The clinicians making referral decisions under real time pressure, with incomplete trial information.

  • Trial sponsors

    The teams and CROs whose studies stall waiting for eligible patients they know are out there.

A cancer patient resting in a treatment chair by a sunlit window

Our interviews

From patient cancer diagnosis to site clinical trial recruitment.

In every conversation with patients, caregivers, oncologists and trial sponsors, we want to understand how finding the right trial works today.

Questions we ask

How does your team recruit patients for a cancer trial today?

Walk us through it, from first referral to enrollment.

Where does recruitment for cancer trials break down for your team?

And why does it break down there?

How often do you face recruitment breakdowns?

For a patient, a practice or a trial team.

Why does getting trial recruitment right matter to you?

What happens when recruitment goes wrong.

What do you do about recruitment breakdowns today?

The workarounds, tools and people you rely on.

Meet the team

The people behind BioKindred

Rooted in the EGFR patient community, with clinical-data, cancer-biology and partnership experience, and a physician advisor.

  • Portrait of Sharon Kassa, BioKindred co-founder and CEO

    Sharon Kassa

    Co-founder & CEO

    Sharon worked at Deloitte on the roughly $2.5B Ethio Telecom IPO and helped raise about $11.1M for six companies through a USAID-backed program. She brings Lung Kindred, the community she founded to connect lung cancer patients and caregivers by mutation.

    Education

    • MA, Business Leadership
    • BA, Management
  • Portrait of Juliet Mirambo, BioKindred co-founder and CTO

    Juliet Mirambo

    Co-founder & CTO

    Juliet is a technical lead developer and value chain manager at Merck KGaA, building systems that match clinical trial drug formulations. She brings work on antibody-drug conjugate initiatives for cancer and a forecasting model for €250M in global planning.

    Education

    • BS, Chemistry and Engineering
  • Portrait of Semaria Kebede, BioKindred co-founder

    Semaria Kebede

    Co-founder & Head of Go-to-Market and Partnerships

    Semaria is an entrepreneur and Mandela Washington Fellow who previously built a technology business. She brings experience in growth strategy, partnerships and customer discovery to BioKindred, where she explores how cancer patients find and navigate relevant clinical trials.

    Education

    • MBA, University of California, Riverside
  • Portrait of Ali Gholamian Moghaddam, BioKindred co-founder

    Ali Gholamian Moghaddam

    Co-founder & Head of Cancer Biology

    Ali is a cancer biology researcher with experience in drug discovery, molecular biology and biomarker detection. He brings research on potential anticancer compounds for lung and colorectal cancer and synthetic biosensors for biomarkers, grounding BioKindred in biomarker-driven cancer science.

    Education

    • PhD candidate, Biology, St. John’s University
    • MS, Biology, University of Louisiana Monroe

Advisor

  • Portrait of Dr. David Lo, BioKindred clinical advisor

    Dr. David Lo

    Clinical Advisor

    David is a practicing family medicine physician, an adjunct professor at Touro College of Osteopathic Medicine and the founder of ProMed United, an evidence-based tutoring and mentorship company for healthcare learners. At BioKindred, he advises on clinical questions.

    Education

    • DO, Rowan-Virtua School of Osteopathic Medicine
    • MBS, Rutgers University

Get in touch

Patients, caregivers, oncologists and trial sponsors: we want to hear from you.

We're talking with everyone on the path from cancer diagnosis to clinical trial recruitment. Book a call, or send us a note.

Or send us a message.

Join the conversation

BioKindred

Advancing access to precision cancer trials.

© 2026 BioKindred. A more inclusive tomorrow for people with cancer.